Navigation Links
Intrinsic Imaging Awarded Phase II Immuno-Oncology Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Date:3/22/2017

Intrinsic Imaging, LLC, an FDA audited and ISO certified medical imaging core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that it has been awarded a multi-year phase II immuno-oncology clinical trial for the treatment of non-small cell lung cancer and small cell lung cancer.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including protocol and charter development, site qualification, site training and management, image transfer, quality control and processing. In addition, Intrinsic Imaging’s full-time board-certified, fellowship trained radiologists will also evaluate the patients’ tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criterion.

“Intrinsic Imaging was selected due to our extensive therapeutic experience and operational excellence in oncology and immuno-oncology clinical trials,” said Todd A. Joron, BSc., MBA, President & COO at Intrinsic Imaging. “With our team of 70 fellowship trained radiologists, robust and scalable clinical imaging technologies and our ISO certified quality management systems, Intrinsic Imaging is ideally positioned to provide our expertise in the assessment of non-small cell lung cancer and other lung cancers.”

Intrinsic Imaging's board-certified team includes 12 oncology focused radiologists with an extensive breadth of experience in clinical trials involving carcinomas, sarcomas, and lymphomas. The company also has significant expertise in a range of assessment criterion including , but not limited to, BIRADS, Cheson, irRECIST, Lugano, Macdonald, mRecist, PERCIST, RANO and RECIST.

Lung cancer is the leading cause of cancer death across the globe, claiming more lives than the next three most common cancers combined. Non-small cell lung cancer accounts for some 85% of lung cancer diagnoses. The five-year survival rate is low often due to most patients having advanced disease at the time of presentation. Intrinsic Imaging proudly lends its expertise on this clinical trial in an effort to help in the development of an effective treatment for lung cancer.

About Intrinsic Imaging, LLC
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001, ISO 13485, ISO 22301 and ISO 27001 certified and GAMP5 compliant medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than seventy full-time board-certified fellowship trained radiologists, robust and scalable clinical imaging technologies and its ISO certified quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world. For more information, please visit http://www.IntrinsicImaging.com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14170750.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Intrinsic Clinical Systems Unveils a New Kind of Clinical Trial Management System
2. New Intrinsically Safe XPP-5454GC LED Headlamp from Nightstick® Now Clips Direct to Hard Hats
3. Dual Magnets Add Convenience to Safety in New Nightstick® XPP-5422GM Intrinsically Safe Dual-LightTM Flashlight
4. Intrinsic Imaging Awarded Medical Device Trial for Percutaneous Tumor Ablation
5. RSNA: Noninvasive Imaging Helps Predict Heart Attacks
6. Functional Imaging Supports Improved Cognition in Parkinson’s Disease Patients After REHACOP
7. Canopy Partners Launches Canopy CARE – An End-To-End Referral Management Platform For Medical Imaging Providers
8. Scottsdale Medical Imaging Recognized with Award from the Southwest Alliance for Excellence.
9. Camellia Women’s Imaging Helping Diminish Breast Cancer Screening Anxiety
10. RSNA: Imaging Links Structural Brain Changes and Cognitive Decline in Parkinson’s
11. NIH Awards Nocturnal Product Development and GW a $2.27M Phase II STTR Grant for Preclinical Development of Cardiac Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and which He does not. Yisrayl says with so many titles and names for ... but he says with a little Scripture, backed with a lot of research, the truth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is ... Côté has 20+ years of experience within the beauty industry, ranging from marketing, ... array of high-end cosmetic brands, retail brands and outlets in Canada and New ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the launch ... a moisturizer with the power of an anti-aging concentrate. , Anogeissus ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... ... Christie Medical Holdings, Inc. , with its market-leading vein finder ... a leader in infusion therapy and pain management. , Intravenous (IV) therapy plays ... patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology: